| Dr Stephen T Joyce, MD, MPH | |
|
1100 W Veterans Pkwy, Yorkville, IL 60560-4728 | |
| (630) 466-3388 | |
| (630) 978-6710 |
| Full Name | Dr Stephen T Joyce |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 1100 W Veterans Pkwy, Yorkville, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871808485 | NPI | - | NPPES |
| 036.081946 | Other | IL | NONE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 036.081946 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Stephen T Joyce, MD, MPH 1100 W Veterans Pkwy, Yorkville, IL 60560-4728 Ph: (630) 466-3388 | Dr Stephen T Joyce, MD, MPH 1100 W Veterans Pkwy, Yorkville, IL 60560-4728 Ph: (630) 466-3388 |
News Archive
When a baby is born, new parents often wonder, "Will he be the next President of the United States?" or "Could she be the one to find a cure for cancer?" But the underlying question for many specialists is, "Is this child 'at risk' for developmental issues?"
Instead, GOP presidential hopeful Mitt Romney will buy private health insurance. News reports describe this step as Romney's effort to make a political point. He supports transforming Medicare into a premium support program and has taken the position that wealthier seniors should pay more for their Medicare benefits.
New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis. According to the study published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, men are at higher risk of more severe fibrosis compared to women prior to menopause, but liver fibrosis severity is similar in men and post-menopausal women.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.
On Sept. 15, the SynCardia temporary Total Artificial Heart was awarded the 2010 Kerrin Rennie Award for Excellence in Medical Technology by the Medical Technology Association of Australia (MTAA).
› Verified 5 days ago